Remove tag competition
article thumbnail

ASH: Argenx cues up a second use for efgartigimod

pharmaphorum

Vyvgart is already approved to treat generalised myasthenia gravis, getting a green light for that indication from the FDA a year ago, and launched with a $225,000 per annum price tag in competition with rival gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).

article thumbnail

With rivals threatening, Argenx scores key myasthenia gravis win

pharmaphorum

Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

pharmaphorum

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

FDA 62
article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

This evolution is leading to additional health benefits and health gains, but they are accompanied by major concerns, as very high price tags raise questions about their affordability.”. In recent years, revolutionary medicines have come with price tags to match, but this is simply a symptom of our current model.

article thumbnail

J&J builds case for antidepressant Spravato with head-to-head trial

pharmaphorum

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems.

article thumbnail

Top Commercial Benefits of Modular Approach

Viseven

Fast TTM directly affects your sales metrics, as being first with something valuable in a market means winning the competition. Metadata tagging allows searching for a needed piece of delivery faster and easier than usual research on the content subject.

article thumbnail

A history of Pfizer

pharmaphorum

It almost hadn’t made it through clinical development, facing problems with ineffective chiral isomers and limited efficacy in animal testing, but showed such impact in human trials that it blew the competition away. For all the latest Pfizer news follow pharmaphorum’s Pfizer tag.